Genetic-Driven Druggable Target Identification and Validation
- 1 July 2018
- journal article
- review article
- Published by Elsevier in Trends in Genetics
- Vol. 34 (7) , 558-570
Abstract
No abstract availableKeywords
Funding Information
- Italian Foundation for Multiple Sclerosis
- Intramural Research Program of the National Institute on Aging
- European Union’s Horizon 2020 Research and Innovation Program (633964)
This publication has 86 references indexed in Scilit:
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Genetics of gene expression in primary immune cells identifies cell type–specific master regulators and roles of HLA allelesNature Genetics, 2012
- Long-range DNA looping and gene expression analyses identify DEXI as an autoimmune disease candidate geneHuman Molecular Genetics, 2011
- Leveraging Genetic Variability across Populations for the Identification of Causal VariantsThe American Journal of Human Genetics, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Statistical independence of the colocalized association signals for type 1 diabetes and RPS26 gene expression on chromosome 12q13Biostatistics, 2008
- Recent and ongoing selection in the human genomeNature Reviews Genetics, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- A haplotype map of the human genomeNature, 2005
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003